Skip to main content
Not investment advice. Educational platform. See Disclaimer.
AMEX: LCTX

Lineage Cell Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for LCTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.19

Lineage Cell Therapeutics, Inc. (AMEX: LCTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 11:28 UTC.

What Lineage Cell Therapeutics, Inc. does

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement therapies based on its proprietary AlloSCOPE manufacturing platform. The company creates mature, differentiated cells derived from pluripotent cell lines to replace cells that have become dysfunctional or lost due to disease or injury, rather than administering stem cells directly to patients. Its most advanced program, OpRegen, is in Phase 2a development with Roche for treating geographic atrophy in dry age-related macular degeneration.

Summarized from Lineage Cell Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.19

Revenue, margins & earnings

FY2021: net loss $43M on revenue $4M$4MFY2021FY2022: net loss $26M on revenue $15M$15MFY2022FY2023: net loss $21M on revenue $9M$9MFY2023FY2024: net loss $19M on revenue $9M$9MFY2024FY2025: net loss $64M on revenue $15M$15MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-07-02
Most recent filed transactions — July 2026:
  • 2026-07-02DirectorOPTION TO PURCHASE COMMON SHARESAward125,000—
  • 2026-07-02DirectorStock Option (Right to Buy)Award125,000—
  • 2026-07-02DirectorStock Option (Right to Buy)Award125,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Lineage Cell Therapeutics, Inc. do?

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement therapies based on its proprietary AlloSCOPE manufacturing platform.

When did LCTX last file with the SEC?

Lineage Cell Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 11:28 UTC. This page is also available as JSON at /api/data?ticker=LCTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for LCTX and 5,000+ tickers.

Create a free account — keep LCTX
For your agent
GET /api/data?ticker=LCTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt